microRNA-34c is a novel target to treat dementias

Authors

  • Athanasios Zovoilis,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
    • These authors contributed equally to this work
  • Hope Y Agbemenyah,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
    • These authors contributed equally to this work
  • Roberto C Agis-Balboa,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Roman M Stilling,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Dieter Edbauer,

    1. DZNE, German Center for Neurodegenerative Diseases Munich, Munich, Germany
    Search for more papers by this author
  • Pooja Rao,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Laurent Farinelli,

    1. Fasteris SA, Geneva, Switzerland
    Search for more papers by this author
  • Ivana Delalle,

    1. Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA
    Search for more papers by this author
  • Andrea Schmitt,

    1. Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao Paulo, São Paulo, Brazil
    2. Department of Psychiatry and Psychotherapy, University of Göttingen, von-Göttingen, Germany
    Search for more papers by this author
  • Peter Falkai,

    1. Department of Psychiatry and Psychotherapy, University of Göttingen, von-Göttingen, Germany
    2. DZNE, German Center for Neurodegenerative Diseases Göttingen, Göttingen, Germany
    Search for more papers by this author
  • Sanaz Bahari-Javan,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Susanne Burkhardt,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Farahnaz Sananbenesi,

    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    Search for more papers by this author
  • Andre Fischer

    Corresponding author
    1. Laboratory for Aging and Cognitive Diseases, European Neuroscience Institute, Göttingen, Germany
    2. Department of Psychiatry and Psychotherapy, University of Göttingen, von-Göttingen, Germany
    3. DZNE, German Center for Neurodegenerative Diseases Göttingen, Göttingen, Germany
    • Corresponding author. Department for Psychiatry and Psychotherapy, European Neuroscience Institute, Grisebach Strasse 3, Göttingen 37077, Germany. Tel.: +49 551 391 0378; Fax: +49 551 399 836; E-mail: afische2@gwdg.de

    Search for more papers by this author

  • There is a Have you seen? (October 2011) associated with this Article.

Abstract

MicroRNAs are key regulators of transcriptome plasticity and have been implicated with the pathogenesis of brain diseases. Here, we employed massive parallel sequencing and provide, at an unprecedented depth, the complete and quantitative miRNAome of the mouse hippocampus, the prime target of neurodegenerative diseases such as Alzheimer's disease (AD). Using integrative genetics, we identify miR-34c as a negative constraint of memory consolidation and show that miR-34c levels are elevated in the hippocampus of AD patients and corresponding mouse models. In line with this, targeting miR-34 seed rescues learning ability in these mouse models. Our data suggest that miR-34c could be a marker for the onset of cognitive disturbances linked to AD and indicate that targeting miR-34c could be a suitable therapy.

Ancillary